Hi doc,
Thanks for doing this. I will most likely not be
Hi doc,
Thanks for doing this. I will most likely not be able to participate in the CCs live and directly, as they are going to be in the middle of the day here in Germany, while I have to work.
So you can add my question from earlier to your email. Let me rephrase them appropriately.
Please give us more details on the last financial deal you have done to raise $2m and the related S1 filing. It does sound to me as if you have given away more than half the company (~150m added to the currently ~90m shares) for lousy proceeds of up to $15m or on average $0.1/share!? Please tell us that this assumption is wrong and give us the specifics of what this deal is all about and how to understand the almost 150m shares mentioned in that S1 filing.
We all know that the company is highly undervalued on the stock market, but was there really no way around even raising the $2m at $0.392/share, i.e. at the low of the year?
Do you see any correlation between the pps plunging in the 2 weeks prior to announemrnt of the closing of this deal and your negotiation with the related hedge funds, who have a track record of pps manipulation? Are you not the least little bit concerned that you have started doing business with yet another "foul bunch of apples"?
How about these specific clauses in your contract with them that might end up giving them a large amount of warrants for free? Is that not giving them an incentive/motivation to continue manipulating the pps and working against your efforts to increase the pps, such that GNBT's stock meets the minimum requirements to be listed on the Nasdaq?
Docj, I would be asking that particular set of questions, if I were able to dial into the cc. Can you add this to your upfront email and if not addressed, can someone asked these questions, either on my behalf or in his/her own name, which I wouldn't mind at all. This is just a major concern for me and I would just like to receive a response no matter how it is reached.
Thanks in advance.
1
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...
Continue Reading
JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...
Continue Reading
Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...
Continue Reading
A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...
Continue Reading
IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...
Continue Reading
Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....
Continue Reading
A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...
Continue Reading
Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...
Continue Reading
Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...
Continue Reading
Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...
Continue Reading
Top 5 Most Recently Viewed Articles
The Unveiling of Roche's Sixth-Generation Troponin T Test Roche has recently been granted a CE Mark for its innovative sixth-generation Troponin T test, which promises to deliver a new level of accuracy that is critical for diagnosing heart attacks. This novel testing solution is designed to enhance sensitivity and precision, allowing for quicker and more reliable...
Continue Reading
Understanding Keurig Dr Pepper's Earnings Potential Keurig Dr Pepper Inc. (NASDAQ: KDP) is preparing to share its third quarter earnings results shortly. Investors eagerly await the disclosures, which are expected to highlight positive financial trends and growth. Analysts predict that the company will report earnings per share of 54 cents, an increase from 51 cents in...
Continue Reading
Uwharrie Capital Corp Reports Strong Year-End Results Uwharrie Capital Corp and its subsidiary, Uwharrie Bank, have recently unveiled impressive financial results that reflect their continued strength and stability in the banking sector. The company reported consolidated total assets of $1.13 billion at the end of the reporting period, demonstrating a noticeable increase...
Continue Reading
Revolutionizing Tourism Through Interactive Web Design In today's fast-paced digital world, engaging younger travellers has become crucial for tourism boards in California. Digital Silk, an award-winning agency renowned for its expertise in digital marketing and web design, is leading the charge to inspire Generation Z and millennials by advocating for the adoption of...
Continue Reading
FOX News Digital Achieves Historic Success in October Leading YouTube with 377 Million Video Views During the month of October, FOX News Digital achieved outstanding milestones, topping the charts in multiplatform engagement. With a staggering 3.7 billion multiplatform minutes and 1.8 billion views, the platform outshined its competitors, establishing its dominance in the...
Continue Reading